Dermira announces initiation of phase 3 program evaluating lebrikizumab
Dermira announced dosing of the first patient in a Phase 3 study evaluating the safety and efficacy of lebrikizumab in adult and adolescent patients ages 12 and older with moderate-to-severe atopic dermatitis, the most common form of eczema. October 09, 2019